« Return to News | CROs/Service Providers

Parexel Profits Rebound in Q3

Wednesday, April 28, 2010 07:12 AM

Parexel came back from a tough second quarter with strong third quarter results, posting a 10.1% increase in service revenues. The CRO, whose year-over-year profits were cut in half in the second quarter due to a cancelled project, reported revenues of $291.2 million in Q3, compared with $264.5 million for the same period last year.

Net income for the quarter totaled $12.8 million, or $0.22 per diluted share, down slightly from $14.2 million, or $0.25 per diluted share, in Q3 2009, but a vast improvement over the last quarter.

“Our performance in the third quarter clearly demonstrates a return to growth, and we are now looking more confidently into the future given our strong new business wins and growth in backlog,” said CEO Josef von Rickenbach. “As we move into our fourth fiscal quarter and gain better perspective on calendar year 2010, we believe that the market for our services is continuing to recover.  In this regard, we have seen a significant increase in the volume and value of pending requests for proposals from our clients.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.